| pubmed-article:10792283 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:10792283 | lifeskim:mentions | umls-concept:C0149615 | lld:lifeskim |
| pubmed-article:10792283 | lifeskim:mentions | umls-concept:C2350463 | lld:lifeskim |
| pubmed-article:10792283 | lifeskim:mentions | umls-concept:C2243049 | lld:lifeskim |
| pubmed-article:10792283 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:10792283 | lifeskim:mentions | umls-concept:C1416643 | lld:lifeskim |
| pubmed-article:10792283 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:10792283 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:10792283 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:10792283 | pubmed:dateCreated | 2000-6-14 | lld:pubmed |
| pubmed-article:10792283 | pubmed:abstractText | We investigated the expression of natural killer cell receptors (NKRs) for HLA-C on peripheral blood mononuclear cells (PBMCs) in 23 allogeneic bone marrow transplantation (allo-BMT) patients to analyse the role of NKRs in alloresponse concerning graft-versus-host disease (GVHD). CD158a expression was low and there was little change in the expression after allo-BMT. Also, there was no difference in the proportion of CD158a+/CD3- after allo-BMT. In contrast, the proportion of CD158b+/CD3- cells, mainly NK cells, increased in the early stage (< 2 months) after allo-BMT and then gradually decreased (3.3 +/- 2.6% before BMT vs. 15.4 +/- 8. 6% in the early stage after BMT, 8.5 +/- 4.9% during the period 3-6 months after BMT and 7.0 +/- 3.0% > 6 months after BMT; P < 0.05). However, CD158b expression on CD3+ T cells increased 3 months after allo-BMT (1.1 +/- 1.1% before BMT vs. 5.1 +/- 7.7% during the period 3-6 months after BMT and 3.0 +/- 2.4% > 6 months after BMT, P < 0. 05). The highest percentages of CD158 expression in patients without chronic GVHD (cGVHD) and those with cGVHD were compared. The percentage of CD158b+/CD3+ cells and also that of CD158b+/CD8+ cells were significantly increased in patients with cGVHD compared with those in patients without cGVHD (2.6 +/- 2.0% vs. 8.0 +/- 11.2% and 2.3 +/- 1.5% vs. 8.3 +/- 11.7% respectively; P < 0.05). The exact clinical relevance of these CD158b-expressing cells is not clear. However, there is an interesting possibility that CD158b-expressing cells play some role in the regulation of GVHD after allo-BMT. | lld:pubmed |
| pubmed-article:10792283 | pubmed:language | eng | lld:pubmed |
| pubmed-article:10792283 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10792283 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:10792283 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10792283 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10792283 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10792283 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10792283 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:10792283 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:10792283 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:10792283 | pubmed:issn | 0007-1048 | lld:pubmed |
| pubmed-article:10792283 | pubmed:author | pubmed-author:KobayashiSS | lld:pubmed |
| pubmed-article:10792283 | pubmed:author | pubmed-author:MoriAA | lld:pubmed |
| pubmed-article:10792283 | pubmed:author | pubmed-author:KobayashiMM | lld:pubmed |
| pubmed-article:10792283 | pubmed:author | pubmed-author:YamamotoYY | lld:pubmed |
| pubmed-article:10792283 | pubmed:author | pubmed-author:TanakaJJ | lld:pubmed |
| pubmed-article:10792283 | pubmed:author | pubmed-author:ImamuraMM | lld:pubmed |
| pubmed-article:10792283 | pubmed:author | pubmed-author:OhtaSS | lld:pubmed |
| pubmed-article:10792283 | pubmed:author | pubmed-author:AsakaMM | lld:pubmed |
| pubmed-article:10792283 | pubmed:author | pubmed-author:HashinoSS | lld:pubmed |
| pubmed-article:10792283 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:10792283 | pubmed:volume | 108 | lld:pubmed |
| pubmed-article:10792283 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:10792283 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:10792283 | pubmed:pagination | 778-83 | lld:pubmed |
| pubmed-article:10792283 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:10792283 | pubmed:meshHeading | pubmed-meshheading:10792283... | lld:pubmed |
| pubmed-article:10792283 | pubmed:meshHeading | pubmed-meshheading:10792283... | lld:pubmed |
| pubmed-article:10792283 | pubmed:meshHeading | pubmed-meshheading:10792283... | lld:pubmed |
| pubmed-article:10792283 | pubmed:meshHeading | pubmed-meshheading:10792283... | lld:pubmed |
| pubmed-article:10792283 | pubmed:meshHeading | pubmed-meshheading:10792283... | lld:pubmed |
| pubmed-article:10792283 | pubmed:meshHeading | pubmed-meshheading:10792283... | lld:pubmed |
| pubmed-article:10792283 | pubmed:meshHeading | pubmed-meshheading:10792283... | lld:pubmed |
| pubmed-article:10792283 | pubmed:meshHeading | pubmed-meshheading:10792283... | lld:pubmed |
| pubmed-article:10792283 | pubmed:meshHeading | pubmed-meshheading:10792283... | lld:pubmed |
| pubmed-article:10792283 | pubmed:meshHeading | pubmed-meshheading:10792283... | lld:pubmed |
| pubmed-article:10792283 | pubmed:meshHeading | pubmed-meshheading:10792283... | lld:pubmed |
| pubmed-article:10792283 | pubmed:meshHeading | pubmed-meshheading:10792283... | lld:pubmed |
| pubmed-article:10792283 | pubmed:meshHeading | pubmed-meshheading:10792283... | lld:pubmed |
| pubmed-article:10792283 | pubmed:meshHeading | pubmed-meshheading:10792283... | lld:pubmed |
| pubmed-article:10792283 | pubmed:meshHeading | pubmed-meshheading:10792283... | lld:pubmed |
| pubmed-article:10792283 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:10792283 | pubmed:articleTitle | Expression of HLA-C-specific natural killer cell receptors (CD158a and CD158b) on peripheral blood mononuclear cells after allogeneic bone marrow transplantation. | lld:pubmed |
| pubmed-article:10792283 | pubmed:affiliation | Haematology and Oncology; Third Department of Internal Medicine; Transfusion Medicine; Laboratory of Pathology, Cancer Institute, Hokkaido University School of Medicine, Sapporo, Japan. jtunaka@med.hokudai.ac.jp | lld:pubmed |
| pubmed-article:10792283 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:10792283 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:10792283 | lld:pubmed |
